Free, paid and Enterprise Tiers
Exploration of pubilc data and novel compounds
Our most sophisticated analyses for clinical trials with omics data available
Classification of ALL patients in a clinical trial as responders or non-responders, regardless of censoring or treatment arm. Stable classes for biomarker mining.
Prediction of patients as responders or non-responders. Our tests show this to to be over 80% accurate on Pfizer open source data.
Phase II and Phase III patient inclusion
Dramatically increase chances of passing Phase III
Resurrect failed trials with targeted subgroups of response
ResponderCDx creates a clinical diagnostic test for drugs. For off-patent or expiring compounds, this can improve their value substantially
Sign up to get our newsletter and stay aware of our latest research, products and SaaS releases.
World leading technology to determine subgroups of response in clinical trials and treatment data.
Led by Professors with decades of research in mathematics, genetics, omics, machine learning and statistics & epidemiology.
Tools to improve chances of passing clinical trials, identify biomarkers of response (companion diagnostics), and getting the right drugs to the right patients.
Mail : [email protected]
Products
Technology
Research
About Us
Contact Us
Copyright ©️ 2025 Datanon Corporation